Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

ClinicalTrials.gov ID: NCT06526793

Public ClinicalTrials.gov record NCT06526793. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Surovatamig (AZD0486) in Participants With Relapsed or Refractory (R/R) B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for LBCL.

Study identification

NCT ID: NCT06526793
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: AstraZeneca; Industry
Enrollment: 270 participants

Conditions and interventions

Conditions

Interventions

Surovatamig Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 26, 2024
Primary completion: Apr 20, 2028
Completion: Oct 20, 2032
Last update posted: Aug 12, 2026

2024 – 2032

United States locations

U.S. sites: 22
U.S. states: 17
U.S. cities: 22

Facility	City	State	ZIP	Site status
Research Site	Phoenix	Arizona	85054	Withdrawn
Research Site	Duarte	California	91010	Recruiting
Research Site	Jacksonville	Florida	32224	Withdrawn
Research Site	Tampa	Florida	33612	Recruiting
Research Site	Chicago	Illinois	60637	Recruiting
Research Site	Iowa City	Iowa	52242	Withdrawn
Research Site	Waukee	Iowa	50263	Recruiting
Research Site	Overland Park	Kansas	66204	Withdrawn
Research Site	Rochester	Minnesota	55905	Recruiting
Research Site	St Louis	Missouri	63110	Withdrawn
Research Site	New Brunswick	New Jersey	08901	Withdrawn
Research Site	New York	New York	10016	Recruiting
Research Site	Charlotte	North Carolina	28204	Recruiting
Research Site	Columbus	Ohio	43210	Recruiting
Research Site	Portland	Oregon	97239	Recruiting
Research Site	Philadelphia	Pennsylvania	19104	Recruiting
Research Site	Pittsburgh	Pennsylvania	15232	Withdrawn
Research Site	Nashville	Tennessee	37203	Recruiting
Research Site	Austin	Texas	78704	Recruiting
Research Site	Houston	Texas	77030	Recruiting
Research Site	San Antonio	Texas	78229	Not yet recruiting
Research Site	Milwaukee	Wisconsin	53226	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 71 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06526793, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 12, 2026 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06526793 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →